Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Otsuka Gives Apple's iPad to Every MR
June 28, 2010
- Zometa Improves OS in Patients with De Novo Multiple Myeloma
June 28, 2010
- Bayer to Strengthen Marketing Structure in General Medicine
June 28, 2010
- Research-Driven Companies Also to Be Blamed for Jam of Generics: Mr Sawai
June 28, 2010
- Pfizer's Crizotinib to Contribute to Personalized Treatment of NSCLC
June 28, 2010
- MTPC Presents Business Improvement Plans to Korosho
June 28, 2010
- Ethical Drugs' Sales Up 10.2% in April: Crecon
June 28, 2010
- Sprycel Effective in First-Line Therapy for CML-CP
June 28, 2010
- Ensure Value-Matched Sales of Drugs: New JPMA Marketing Committee Chairman
June 28, 2010
- FPMAJ Subcommittee Calls For Full-Scale Introduction of Premium for Development of New Drugs
June 28, 2010
- 4-Year Follow-up Data from Sprycel-Treated Patients Announced
June 28, 2010
- Pfizer, Eisai Launch Lyrica
June 21, 2010
- GL for Non-Clinical Evaluation of Anti-Malignant Tumor Agents Issued
June 21, 2010
- Eplerenone Meets Primary Endpoint Early in PIIIb: Pfizer
June 21, 2010
- Bayer to Expand Packing Line for Chewable Tablets
June 21, 2010
- Clinical Trial Costs Can Be Cut Using iPad: Mr Hasegawa
June 21, 2010
- Lubiprostone Meets Primary Endpoint in PIII in Japan
June 21, 2010
- Asahi Kasei's Pharm Sales to Fall below Target Set in Mid-Term Management Plan
June 21, 2010
- New OTC Drugs Consultation Services Started
June 21, 2010
- Diovan Shows Hypotensive Effects in Elderly Japanese Patients
June 21, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…